Pancreatic Cancer: Who Benefits from Curative Resection?
Surgical resection is the only chance for cure of pancreatic cancer. Unfortunately, the majority of patients have grossly unresectable disease. Patients with stage I or II disease according to the criteria of the International Union Against Cancer (UICC) should be considered for potentially curative...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2002-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2002/174320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560443296579584 |
|---|---|
| author | HG Beger F Gansauge G Leder |
| author_facet | HG Beger F Gansauge G Leder |
| author_sort | HG Beger |
| collection | DOAJ |
| description | Surgical resection is the only chance for cure of pancreatic cancer. Unfortunately, the majority of patients have grossly unresectable disease. Patients with stage I or II disease according to the criteria of the International Union Against Cancer (UICC) should be considered for potentially curative surgery. The goal of surgery is to remove the entire tumour with no residual disease (oncological R0 resection), which requires extensive resection of the surrounding tissues. Even if lymph nodes are histologically free of disease, molecular biological techniques reveal infiltration with cancer cells in 50% of cases. Therefore, extensive local resection combined with radical resection of lymphatic tissue, including lymph nodes around the head of the pancreas, retroperitoneal tissue and neural plexus around the great vessels, affords a longer median survival time than standard resection alone. Even patients with UICC stage III disease can undergo aggressive surgical treatment, but their chances for long term survival are low. Some patients develop severe diarrhea after circumferential removal of nerve tissue around the superior mesenteric artery. Adjuvant radiochemotherapy also provides a modest prolongation of survival. Despite these advances, the prognosis for pancreatic cancer is still poor, and spread of tumour within the peritoneum and to the liver is common postoperatively. |
| format | Article |
| id | doaj-art-66bd5ce750824700a3d6276bc419bec4 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2002-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-66bd5ce750824700a3d6276bc419bec42025-02-03T01:27:34ZengWileyCanadian Journal of Gastroenterology0835-79002002-01-0116211712010.1155/2002/174320Pancreatic Cancer: Who Benefits from Curative Resection?HG Beger0F Gansauge1G Leder2Department of General Surgery, University of Ulm, Ulm, GermanyDepartment of General Surgery, University of Ulm, Ulm, GermanyDepartment of General Surgery, University of Ulm, Ulm, GermanySurgical resection is the only chance for cure of pancreatic cancer. Unfortunately, the majority of patients have grossly unresectable disease. Patients with stage I or II disease according to the criteria of the International Union Against Cancer (UICC) should be considered for potentially curative surgery. The goal of surgery is to remove the entire tumour with no residual disease (oncological R0 resection), which requires extensive resection of the surrounding tissues. Even if lymph nodes are histologically free of disease, molecular biological techniques reveal infiltration with cancer cells in 50% of cases. Therefore, extensive local resection combined with radical resection of lymphatic tissue, including lymph nodes around the head of the pancreas, retroperitoneal tissue and neural plexus around the great vessels, affords a longer median survival time than standard resection alone. Even patients with UICC stage III disease can undergo aggressive surgical treatment, but their chances for long term survival are low. Some patients develop severe diarrhea after circumferential removal of nerve tissue around the superior mesenteric artery. Adjuvant radiochemotherapy also provides a modest prolongation of survival. Despite these advances, the prognosis for pancreatic cancer is still poor, and spread of tumour within the peritoneum and to the liver is common postoperatively.http://dx.doi.org/10.1155/2002/174320 |
| spellingShingle | HG Beger F Gansauge G Leder Pancreatic Cancer: Who Benefits from Curative Resection? Canadian Journal of Gastroenterology |
| title | Pancreatic Cancer: Who Benefits from Curative Resection? |
| title_full | Pancreatic Cancer: Who Benefits from Curative Resection? |
| title_fullStr | Pancreatic Cancer: Who Benefits from Curative Resection? |
| title_full_unstemmed | Pancreatic Cancer: Who Benefits from Curative Resection? |
| title_short | Pancreatic Cancer: Who Benefits from Curative Resection? |
| title_sort | pancreatic cancer who benefits from curative resection |
| url | http://dx.doi.org/10.1155/2002/174320 |
| work_keys_str_mv | AT hgbeger pancreaticcancerwhobenefitsfromcurativeresection AT fgansauge pancreaticcancerwhobenefitsfromcurativeresection AT gleder pancreaticcancerwhobenefitsfromcurativeresection |